Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Testování přidání protirakovinné virové terapie Telomelysin™ k chemoradiaci u pacientů s pokročilým karcinomem jícnu a nejsou kandidáty na chirurgii

9. září 2026 aktualizováno: NRG Oncology

Fáze I studie s expanzní kohortou OBP-301 (Telomelysin™) a definitivní chemoradiací pro pacienty s lokálně pokročilým karcinomem jícnu a gastroezofageálního karcinomu, kteří nejsou kandidáty na chirurgii

This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.

Přehled studie

Postavení

Aktivní, ne nábor

Podmínky

Detailní popis

PRIMARY OBJECTIVE:

I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.

SECONDARY OBJECTIVES:

I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.

II. To assess the number of clinical complete responses (cCR).

III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.

EXPLORATORY OBJECTIVE:

I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.

OUTLINE:

This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.

Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.

Typ studie

Intervenční

Zápis (Aktuální)

16

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • California
      • Duarte, California, Spojené státy, 91010
        • City of Hope Comprehensive Cancer Center
      • South Pasadena, California, Spojené státy, 91030
        • City of Hope South Pasadena
      • Upland, California, Spojené státy, 91786
        • City of Hope Upland
    • Florida
      • Tampa, Florida, Spojené státy, 33612
        • Moffitt Cancer Center
    • Kansas
      • Fairway, Kansas, Spojené státy, 66205
        • University of Kansas Clinical Research Center
      • Kansas City, Kansas, Spojené státy, 66160
        • University of Kansas Cancer Center
      • Westwood, Kansas, Spojené státy, 66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02114
        • Massachusetts General Hospital Cancer Center
    • New Jersey
      • Basking Ridge, New Jersey, Spojené státy, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Middletown, New Jersey, Spojené státy, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, Spojené státy, 07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack, New York, Spojené státy, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, Spojené státy, 10604
        • Memorial Sloan Kettering Westchester
      • New York, New York, Spojené státy, 10065
        • Memorial Sloan Kettering Cancer Center
      • Uniondale, New York, Spojené státy, 11553
        • Memorial Sloan Kettering Nassau
    • Ohio
      • Columbus, Ohio, Spojené státy, 43210
        • Ohio State University Comprehensive Cancer Center
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • UT MD Anderson Cancer Center

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration

    • Gastroesophageal junction tumors must be Siewert type I/II
  • Required diagnostic workup for study entry:

    • History/physical examination prior to registration
    • Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
    • Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
    • Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
    • Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration

  • Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)

  • Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)

  • AST/ALT ≤ 2.5 x ULN

  • Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;

  • Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures

  • Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months

  • Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device

  • The patient must provide study-specific informed consent prior to study entry

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)

    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of metastatic disease including:

    • Positive malignant cytology of the pleura, pericardium or peritoneum
    • Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
    • Tracheoesophageal fistula
    • Radiographic evidence of distant organ involvement
    • Non-regional lymph nodes that cannot be contained within a radiation field
  • More than 1 esophageal lesion

  • Prior systemic chemotherapy for the study cancer

  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

  • Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis

  • For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse

  • Uncontrolled diabetes

  • Infection requiring IV antibiotics at the time of registration

  • Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry

  • Received live vaccine within 30 days prior to registration

  • Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab

  • Breast feeding females

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Treatment (OBP-301, carboplatin, paclitaxel, radiation)

Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.

Intravenously (IV)

Ostatní jména:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatin
  • Paraplatin AQ
  • Paraplatina
  • Platinwas
  • Ribocarbo

Intravenously (IV)

Ostatní jména:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat

Daily fractions

Ostatní jména:
  • Radioterapie rakoviny
  • Ozářit
  • Ozářené
  • Ozáření
  • Záření
  • Radiační terapie, NOS
  • Radioterapeutika
  • RT
  • Terapie, záření
  • RADIOTERAPIE

Intra-tumoral injection

Ostatní jména:
  • OBP-301
  • Telomelysin™

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
Časové okno: From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.

Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:

  • Any grade ≥3 adverse event EXCEPT for the following:

    • Grade 3 nausea/vomiting
    • Grade 3 esophagitis or dehydration
    • The first occurrence of grade 3/4 neutropenia
    • Grade 3/4 lymphopenia (since this is a known toxicity of chemoradiation and OBP-301)
  • Any toxicity that leads to a >14-day cumulative delay in chemoradiation.

If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL).

From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Počet účastníků naživu za 1 a 2 roky
Časové okno: Po 1 a 2 letech
Po 1 a 2 letech
Number of Participants by Highest Grade Adverse Event Reported
Časové okno: From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.

The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
Number of Participants With Clinical Complete Response (cCR)
Časové okno: 6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.

Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:

  • Complete case analysis only includes eligible participants who started protocol treatment and were assessed for cCR;
  • Sensitivity analysis includes all eligible participants who started protocol treatment and counts participants without an assessment as not achieving a cCR.
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
Number of Participants Alive Without Progression at 1 and 2 Years
Časové okno: At 1 and 2 years

Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease.

At 1 and 2 years

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Geoffrey Y Ku, NRG Oncology

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

2. prosince 2021

Primární dokončení (Aktuální)

6. října 2024

Dokončení studie (Odhadovaný)

6. října 2029

Termíny zápisu do studia

První předloženo

12. května 2020

První předloženo, které splnilo kritéria kontroly kvality

12. května 2020

První zveřejněno (Aktuální)

18. května 2020

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

1. října 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • NRG-GI007
  • U10CA180868 (Grant/smlouva NIH USA)
  • NRG-GI007 (Jiný identifikátor: CTEP)
  • NCI-2020-02320 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
  • NRG-GI007 (Jiný identifikátor: NRG Oncology)

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit